GlassScriptPhysician profile
Jacob Webster
NPI 1306454616
$2,543.53
in general payments reported to CMS, 2019-2025
12 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $316 · 2021: $678 · 2022: $419 · 2023: $465 · 2024: $328 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $722.78 | 2020-2024 | Precision 1, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $309.77 | 2022-2024 | Acuvue |
| Sun Pharmaceutical Industries INC. | $237.43 | 2021 | |
| Glaukos Corporation | $222.20 | 2023 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Novartis Pharmaceuticals Corporation | $208.35 | 2021-2023 | |
| Abbvie INC. | $196.82 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $168.83 | 2023-2025 | Miebo, Xiidra, Infuse |
| Oyster Point Pharma, INC. | $142.96 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $129.53 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $120.75 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $69.45 | 2024-2025 | Xdemvy |
| Allergan, INC. | $14.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.